Treatment of systemic sclerosis

Area of Science:

• Rheumatology
• Immunology
• Dermatology

Background:

• Systemic sclerosis (scleroderma) is a complex autoimmune disease characterized by fibrosis and vascular abnormalities.
• Accurate patient classification into diffuse cutaneous and limited cutaneous subsets is crucial for effective management.
• Anticipating and managing complications are key to improving patient prognosis.

Purpose of the Study:

• To outline the critical aspects of systemic sclerosis management.
• To identify high-risk patient groups and potential therapeutic targets.
• To highlight recent advancements in treating scleroderma complications, particularly renal involvement.

Main Methods:

• Review of current understanding in systemic sclerosis classification and management strategies.
• Identification of key organ systems at risk for involvement (intestine, lung, heart, kidney).
• Discussion of therapeutic targets including vascular endothelium, mononuclear cells, and fibroblasts, and agents under investigation.

Main Results:

• Patients with early diffuse systemic sclerosis and rapid skin thickening face the highest risk of internal organ involvement.
• Disease-modifying therapy should be considered for high-risk patients.
• Angiotensin-converting enzyme inhibitors and advanced renal support have shown success in reversing kidney complications.

Conclusions:

• Systemic sclerosis management requires precise patient stratification and proactive complication anticipation.
• Emerging therapies and established treatments offer improved quality of life and prognosis.
• The disease is not considered hopeless, with significant advancements in managing severe manifestations like renal crisis.